No decision has been made as to whether the company will engage in a transaction or transactions and there can be no assurance that the review of strategic business options will result in any transaction, or the terms or timing of any potential transaction. The company has experienced volume of 6,241,062 shares while on average the company has a capacity of trading 668.73K share. These holdings make up 36.05% of the company's outstanding shares. Moving toward ratio analysis, it has current ratio of 2.40 and quick ratio was calculated as 2.20.
The firm's 50-day moving average is $4.05 and its 200 day moving average is $4.64.
Best time to invest in stock market is when things are on odd side, and it's not easy how to pick stocks.
On October 31, 2016, the Company completed its acquisition of the USA rights to Toprol-XL and its now marketed Authorized Generic (AG). The firm now has a "buy" rating on the stock. The Low Price target projection by analysts is $7.5 and the Mean Price Target is $8.75.
Cempra, Inc. (NASDAQ:CEMP) yearly performance is -78.85%. The company's previous year sales total was 5.97 Million. (NASDAQ:ARLZ)'s stock about -46.97% from the 50-day high and 23.90% away from the 50-day low.
When we look at the Analyst Recommendations of the stock, the company has 3 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell. During the last trade, stock's minimum price has been reached out at $2.37 while the maximum trading price moved at $3.32. ARLZ reported $-0.48 earnings per share for the quarter, missing the analyst consensus estimate by $-0.20.
For the three months ended December 31, 2016 there was $6.8 million of amortization of intangible assets acquired through the acquisitions of Tribute, Zontivity and the Toprol-XL franchise and $4.4 million of impairment charges of intangible assets acquired through the Tribute Acquisition. The analysts offering Earnings Estimates for the company were believing that Aralez Pharmaceuticals Inc. They expect $-0.34 EPS, up 15.00% or $0.06 from last year's $-0.4 per share.
For the current quarter, the highest estimate analysts provided is 30.5 Million and the lowest is 30.5 Million. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. with MarketBeat.com's FREE daily email newsletter. (NASDAQ:ARLZ) is under coverage by number of analysts.
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ)'s price to sales ratio for trailing twelve months is 4.01 and price to book ratio for most recent quarter is 1.06. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has fallen 45.95% over the past 6 months and is downtrending. (NASDAQ:ARLZ) could bring EPS of $-0.37/share.
The Stock now has the market capitalization of $161.4 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 14.76% and monthly volatility of 6.97% respectively.